

# Hepato-Biliary CHBG NEWSLETTER

ISSN 1901-6301

Volume 20, Issue 2

October 2016

#### **IN THIS ISSUE**

PUBLICATIONS IN THE COCHRANE LIBRARY (THE CLIB). ISSUE 3 OF 2016 TO ISSUE 9 OF 2016

#### PAST EVENTS

JOINT EASL -- CHBG WORKSHOP 13 APRIL, 2016 AND CHBG EXHIBITION DURING THE INTERNATIONAL LIVER® CONGRESS<sup>TM</sup>, BARCELONA, SPAIN.

#### **FUTURE EVENTS**

COCHRANE COLLOQUIUM. SEOUL, SOUTH KOREA, 23 TO 27 OCTOBER 2016

THE 37TH BI-ANNUAL CHBG MEETING (AFFILIATED LIVER® MEETING EVENT) AND EXHIBITION DURING THE LIVER® MEETING. BOSTON, USA, 11 TO 15 NOVEMBER 2016

#### **VISITORS**

CHBG MEETING PROGRAMME. BOSTON, USA, 13 NOVEMBER 2016



## Use of Cochrane Reviews to inform WHO guidelines

....During the past 20 years, Cochrane has helped to transform the way health decisions are made. Cochrane contributors - 37,000 from more than 130 countries - work together to produce ...(www.cochrane.org/)

Cochrane training webpage http://training.cochrane.org/

The numbering is a continuation from Vol. 20, Issue 1, 2016

PUBLICATIONS IN THE COCHRANE LIBRARY (THE CLIB). ISSUE 3 OF 2016 THROUGH ISSUE 9 OF 2016

#### NEW REVIEWS

191. Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease. Pavlov CS, Casazza G, Semenistaia M, Nikolova D, Tsochatzis E, Liusina E, Ivashkin VT, Gluud C. 192. Non-steroid anti-inflammatory drugs for biliary colic. Fraquelli M, Casazza G, Conte D, Colli A

#### UPDATED REVIEWS

75. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Gluud LL, Vilstrup H, Morgan MY.

76. Booster dose vaccination for preventing hepatitis B. Poorolajal J, Hooshmand E.

#### NEW AND MAJOR UPDATED PROTOCOLS

327. Beta-blockers alone or in combination with isosorbide mononitrate for secondary prevention of bleeding from gastro-esophageal varices in adults with cirrhosis and gastro-oesophageal varices. Kimer N, Naver AV, Thiele M, Krag A, Gluud LL.

328. N-acetylcysteine for non-paracetamol (acetaminophen)-related acute liver failure. Siu JTP, Tejani AM, Nguyen T, Turgeon RD. 329. Continued lamivudine for adults with lamivudine-resistant chronic hepatitis B virus infection. Mok S, Mohan S, Hunter KM, Wang YR, Judge TA.

#### Volume 20, Issue 1

330. Direct-acting antivirals for chronic hepatitis C. Jakobsen JC, Nielsen EE, Feinberg J, Fobian K, Katakam KKumar, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. 331. Interferon for people with lamivudineresistant chronic hepatitis B virus infection. Mok S. Mohan S, Hunter KM, Wang YR, Judge TA. 332. Combination of three-dimensional conformal radiotherapy and transcatheter arterial chemoembolisation versus transcatheter arterial chemoembolisation for primary hepatocellular carcinoma. Lu L, Zeng J, Wen Z. 333. Transabdominal ultrasound or endoscopic ultrasound for diagnosis of gallbladder polyps. Wennmacker SZ, Lamberts MP, Drenth JPH, Gurusamy KS, van Laarhoven CJHM. 334. Glucocorticosteroids for people with alcoholic hepatitis (Update). Pavlov CS, Tsochatzis E, Casazza G, Nikolova D, Volcek E, Gluud C. 335. FibroTest, transient elastography method, and combined FibroTest and transient elastography method for diagnosis of severe hepatic fibrosis and cirrhosis in adults with chronic hepatitis C. Pavlov CS, Casazza G, Nikolova D, Tsochatzis E, Ivashkin VT, Gluud C. 336. Ammonia scavenging agents for people with cirrhosis and hepatic encephalopathy. Zacharias HD, Zacharias AP, Oliveira Ferreira A, Morgan MY, Gluud LL.

337. Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomy (Update). Tyraskis A, Parsons C, Davenport M. 338. Expanded polytetrafluoroethylene (ePTFE)-covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis. Li T, Sun P, Belgaumkar AP, Sun Y, Cheng X, Zheng Q.

339. Fish oil-based lipid emulsions versus standard lipid emulsions for treatment of parenteral nutrition-associated liver disease in children. Alberti G, Castet A, Villarroel del Pino LA, Cifuentes LI, Rivera-Cornejo M, Gana JC.

340. Contrast-enhanced ultrasound compared with computed tomography, magnetic resonance imaging, and positron emission tomography for diagnosing liver metastases in people with newly diagnosed colorectal cancer. Lund M, Bjerre T Abramovitz, Grønbæk H, Mortensen F, Kragh Andersen P.

#### NEW REGISTERED TITLES

505. Aluminium vaccine adjuvants versus other aluminium adjuvants or different adjuvants in humans: systematic review of harms with metaanalysis and Trial Sequential Analysis of randomised clinical trials and estimations of occurrence in observational studies. Gluud C. 506. Aluminium vaccine adjuvants versus placebo or no intervention in humans: systematic review of harms with meta-analysis and Trial Sequential Analysis of randomised clinical trials and estimations of occurrence in observational studies. 507. Aminoglycosides and metronidazole for people with cirrhosis and hepatic encephalopathy. Jeyaraj R, Morgan MY, Gluud LL. 508. Bicarbonate for acute acidosis. Korang SK, Feinberg J, Nielsen EE, Gluud C, Jakobsen JC, Safi S. 509. Banding ligation versus no intervention for primary prevention in adults with oesophageal varices. Gluud LL, Morgan MY. 510. Perioperative antioxidants for outcomes in surgical patients. McKenna H, Martin D, Gurusamy

#### PAST EVENTS

KS.

JOINT EASL -- CHBG WORKSHOP 13 APRIL, 2016 AND CHBG EXHIBITION DURING THE INTERNATIONAL LIVER® CONGRESS™, BARCELONA, SPAIN
A joint workshop, EASL – CHBG, took place
Wednesday 13 April 2016, from 08:00 to 11:00 in Hall 8.0-F8 of Fira Barcelona.
Chairs: Christian Gluud (DK) (CHBG), Cecilia Rodrigues (PT) (EASL).

There were more than 100 people who came to listen to the presentations. The large audience demonstrated the interest in The CHBG work when

#### Volume 20, Issue 1

properly announced in the EASL programme.

We thank all presenters, chairs, and all people who attended The CHBG meeting as well as those who visited The CHBG exhibition stand.

#### **FUTURE EVENTS**

COCHRANE COLLOQUIUM. SEOUL, SOUTH KOREA, 23 TO 27 OCTOBER 2016

The Cochrane Colloquium comes to East Asia for the first time in almost 25 years. For the scientific program and other details, please visit https://colloquium.cochrane.org/.

THE 37<sup>TH</sup> BI-ANNUAL CHBG MEETING (AFFILIATED LIVER® MEETING EVENT) AND EXHIBITION DURING THE LIVER® MEETING. BOSTON, USA. 11 TO 15 NOVEMBER 2016

The 37th bi-annual The CHBG meeting, affiliate event at The Liver Meeting® will be run

**November 13, 2016**, from **6:30pm to 8:00pm**, in room "**Brandeis**", at the **Marriott Boston Copley** 

Place, Boston, MA, USA.

To attend the meeting is free of charge and is opened to anyone. The meeting programme is on the last page of this Newsletter, and you can also find it at the CHBG website <hbg.cochrane.org>

#### **VISITORS**

**Jane Campos**, from the Philippines, paid us a two-days' visit on 18 and 19 of September. Jane is working on the Clevudine in people with chronic hepatitis B virus infection review.

Daria Varganova, from Russia, is on a monthly working visit at the Editorial Team office of the CHBG in Copenhagen, Denmark. The period of her stay is 20 of September to 20 of October 2016. Daria Varganova is working on the 'Glucocorticosteroids for people with alcoholic hepatitis' systematic review, based on the updated protocol.

The Cochrane Hepato-Biliary Group (The CHBG) Newsletter is written, edited, and published in electronic and paper format by Dimitrinka Nikolova and Christian Gluud at The CHBG Editorial Office in Copenhagen, Denmark.

It is issued twice a year and it is also distributed for free world-wide to all people on The CHBG member list who have contributed, are contributing, or have shown interest in the work of The CHBG or in this CHBG Newsletter.

The purpose with The CHBG Newsletter is to inform its readers about activities of The CHBG.

Editorial CHBG staff at The CHBG Editorial Office

Christian Gluud, Co-ordinating & Criticism Editor, E-mail: cgluud@ctu.dk; Dimitrinka Nikolova, Managing Editor, E-mail: dimitrinka.nikolova@ctu.dk; Sarah Louise Klingenberg, Information Specialist, E-mail: slk@ctu.dk

#### **Postal address**

The Cochrane Hepato-Biliary Group/The Copenhagen Trial Unit,
Centre for Clinical Intervention Research
Department 7812, Rigshospitalet, Blegdamsvej 9, Copenhagen Ø, DK-2100
Tel. +45 3545 7169 or +45 3545 7175 Fax +45 3545 7101
Web site: hbg.cochrane.org

Visiting address
Department 7812, Tagensvej 22, 2nd floor, Copenhagen N, DK-2200



## THE COCHRANE HEPATO-BILIARY GROUP

### **BI-ANNUAL MEETING PROGRAMME**

The 37th bi-annual Cochrane Hepato-Biliary Group (The CHBG) meeting, affiliate event\* at The Liver Meeting®, will be run

November 13, 2016, from 6:30pm to 8:00pm, in room "Brandeis",

at the Marriott Boston Copley Place, Boston, MA, USA.

You are kindly invited to participate in the meeting while attending The Liver Meeting® 2016/the 67<sup>th</sup> AASLD Annual Meeting.

#### There is no registration fee.

Chair: Christian Gluud (DK).

| 6:30pm to 6:35pm | Welcome and program introduction.                                                                                                     | C Gluud (DK).                                                                                                              |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| 6:35pm to 6:55pm | Nutrition support in hospitalised adults at nutritional risk. Cochrane systematic review.                                             | J Feinberg (DK), EE Nielsen (DK), SK Korang (DK), K Halberg Engell (DK), MS Rasmussen (DK), K Zhang (CN), et al.           |
| 6:55pm to 7:15pm | Direct-acting antivirals for chronic hepatitis C. Cochrane systematic review.                                                         | JC Jakobsen (DK), <u>EE Nielsen</u> ( <u>DK)</u> , J Feinberg (DK), KK Katakam (DK), G Hauser (HR), G Poropat (HR), et al. |
| 7:15pm to 7:35pm | A sustained virologic response cannot be considered a cure of hepatitis C: a systematic review of natural history studies. An update. | R.S. Koretz, USA.                                                                                                          |
| 7:35pm to 7:55pm | L-ornithine L-aspartate for people with cirrhosis and hepatic encephalopathy. Cochrane systematic review.                             | CS Stokes (DE), ET Goh<br>(UK), H Vilstrup (DK), MY<br>Morgan (UK), <u>LL Gluud (UK)</u> .                                 |
| 7:55pm to 8:00pm | Questions and closing remarks.                                                                                                        | All.                                                                                                                       |

<sup>\*</sup>This is not an official event of the American Association for the Study of Liver Diseases.



Improving healthcare decision-making globally, through systematic reviews of the effects of healthcare interventions, published in *The Cochrane Library*.

The CHBG website: hbg.cochrane.org